Abstract
Alzheimer’s disease is the most common cause of dementia in the elderly, and no disease-modifying therapy is yet available for this devastating pathology. Deposition of different physicochemical forms of amyloid-β peptides is a critical phase in the pathogenesis of Alzheimer’s disease. β-Site amyloid precursor protein cleaving enzyme 1 (BACE-1) is a major enzyme responsible for amyloid-β production; therefore, inhibition of this enzyme represents a promising approach for the discovery of amyloid-β-lowering agents. In this study, a series of novel 2,6-dialkyl-4-chromon-3-yl-1,4-dihydropyridine-3,5-dicarboxylates (14–23) were synthesized and assessed as BACE-1 inhibitors using the Förster resonance energy transfer-based enzyme assay. Synthesized dihydropyridines exhibited weak-to-relatively-good BACE-1 inhibitory activities. Enzyme inhibitory activities ranged from 6.84 ± 6.62 (23) to 51.32 ± 1.04 (14) percent enzyme inhibitions at the concentration of 10 μM. The structure–activity relationship study showed that the presence of 4-[7-(ethanoyloxy)-4-oxo-4H-chromen-3-yl] moiety at C4 position of dihydropyridine ring (14, 16 and 18) confers higher activity compared with other substitutions at this position. Docking simulation predicted a key H-bond interaction between Asp32 residue and dihydropyridine NH group. Moreover, all docked dihydropyridines made good hydrophobic contacts with S1 and S2 subpockets of BACE-1. A good correlation between estimated binding affinities (pKi) and experimental BACE-1 inhibitory activities at 10 μM was obtained (R 2 = 0.639). The findings of this study suggested that 2,6-dialkyl-4-chromon-3-yl-1,4-dihydropyridine-3,5-dicarboxylates could be promising scaffolds for the discovery of novel BACE-1 inhibitors for management of Alzheimer’s disease.
Similar content being viewed by others
References
Bassil N, Grossberg GT (2009) Novel regimens and delivery systems in the pharmacological treatment of Alzheimer’s disease. CNS Drugs 23(4):293–307
Chand K, Prasad S, Tiwari RK, Shirazi AN, Kumar S, Parang K, Sharma SK (2014) Synthesis and evaluation of c-Src kinase inhibitory activity of pyridin-2(1H)-one derivatives. Bioorganic Chem 53:75–82
Chhillar AK, Arya P, Mukherjee C et al (2006) Microwave-assisted synthesis of antimicrobial dihydropyridines and tetrahydropyrimidin-2-ones: novel compounds against aspergillosis. Bioorganic Med Chem 14(4):973–981
Chhillar AK, Yadav V, Kumar A, Kumar M, Parmar VS, Prasad A, Sharma GL (2009) Differential expression of Aspergillus fumigatus protein in response to treatment with a novel antifungal compound, diethyl 4-(4-methoxyphenyl)-2,6-dimethyl-1,4-dihydropyridin-3,5 dicarboxylate. Mycoses 52(3):223–227
Choi SJ, Cho JH, Im I et al (2010) Design and synthesis of 1, 4-dihydropyridine derivatives as BACE-1 inhibitors. Eur J Med Chem 45(6):2578–2590
Cosconati S, Forli S, Perryman AL, Harris R, Goodsell DS, Olson AJ (2010) Virtual screening with AutoDock: theory and practice. Expert Opin Drug Discov 5(6):597–607
Edraki N, Firuzi O, Foroumadi A, Miri R, Madadkar-Sobhani A, Khoshneviszadeh M, Shafiee A (2013) Phenylimino-2H-chromen-3-carboxamide derivatives as novel small molecule inhibitors of β-Secretase (BACE1). Bioorganic Med Chem 21(8):2396–2412
Ghosh AK, Brindisi M, Tang J (2012) Developing β-secretase inhibitors for treatment of Alzheimer’s disease. J Neurochem 1:71–83
John V, Beck J, Bienkowski M, Sinha S, Heinrikson R (2003) Human β-secretase (BACE) and BACE inhibitors. J Med Chem 46:4625–4630
Kumar S, Singh BK, Pandey AK, Eycken EVD, Parmar VS, Ghosh B (2007) A chromone analog inhibits TNF-α induced expression of cell adhesion molecules on human endothelial cells via blocking NF-κB activation. Bioorganic Med Chem 15:2957–2962
Kumar RS, Idhayadhulla A, Abdul Nasser AJ, Selvin J (2011) Synthesis and anticoagulant activity of a new series of 1,4-dihydropyridine derivatives. Eur J Med Chem 46(2):804–810
Lahiri DK, Maloney B, Long JM, Greig NH (2014) Lessons from a BACE1 inhibitor trial: off-site but not off base. Alzheimers Dement 10(5 Suppl):S411–S419
McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM (1984) Clinical diagnosis of Alzheimer’s disease. Neurology 34(7):939–944
Miri R, Javidnia K, Mirkhani H, Kazemi F, Hemmateenejad B, Edraki N, Mehdipour AR (2008) Synthesis and in vitro dual calcium channel antagonist-agonist activity of some 1, 4-dihydo-2, 6-dimethyl-3-nitro and cyano-4-(1-methyl-5-nitro-1H-imidazol-2-yl)-5-pyridinecarboxylates. DARU 16(4):263–270
Miri R, Motamedi R, Rezaei MR, Firuzi O, Javidnia A, Shafiee A (2010) Design, synthesis and evaluation of cytotoxicity of novel chromeno [4,3-b] quinoline derivatives. Arch Pharm 1:111–118
Miri R, Firuzi O, Peymani P, Zamani M, Mehdipour A, Heydari Z, Masteri Farahani M, Shafiee A (2012) Synthesis, cytotoxicity, and QSAR study of new aza-cyclopenta [b] fluorene-1,9-dione derivatives. Chem Biol Drug Des 79(1):68–75
Morris GM, Huey R, Lindstrom W, Sanner MF, Belew RK, Goodsell DS, Olson AJ (2009) AutoDock4 and AutoDockTools4: automated docking with selective receptor flexibility. J Comput Chem 30(16):2785–2791
Nohra A, Umatani T, Sanno Y (1974) Studies on antianaphylactic agents-I: a facile synthesis of 4-oxo-4H-1-benzopyran-3-carboxaldehydes by Vilsmeier reagents. Tetrahedron 30:3553–3561
Putta S, Beroza P (2007) Shapes of things: computer modeling of molecular shape in drug discovery. Curr Top Med Chem 7(15):1514–1524
Rajapakse HA, Nantermet PG, Selnick HG et al (2006) Discovery of oxadiazoyl tertiary carbinamine inhibitors of beta-secretase (BACE-1). J Med Chem 49(25):7270–7273
Razzaghi-Asl N, Firuzi O, Hemmateenejad B, Javidnia K, Edraki N, Miri R (2013) Design and synthesis of novel 3,5-bis-N-(aryl/heteroaryl) carbamoyl-4-aryl-1,4-dihydropyridines as small molecule BACE-1 inhibitors. Bioorganic Med Chem 21:6893–6909
Reitz C, Brayne C, Mayeux R (2011) Epidemiology of Alzheimer disease. Nat Rev Neurol 7(3):137–152
Sanner MF (1999) Python: a programming language for software integration and development. J Mol Graph Model 17(1):57–61
Selkoe D (2008) Soluble oligomers of the amyloid β-protein impair synaptic plasticity and behavior. Behav Brain Res 192(1):106–113
Sellers RP, Alexander LD, Johnson VA et al (2010) Design and synthesis of Hsp90 inhibitors: exploring the SAR of Sansalvamide A derivatives. Bioorganic Med Chem Lett 18:6822–6856
Silvestri R (2009) Boom in the development of non-peptidic beta-secretase (BACE1) inhibitors for the treatment of Alzheimer’s disease. Med Res Rev 29(2):295–338
Sinha S, Anderson JP, Barbour R, Basi G, Caccavello R, Davis D, Doan M, Dovey H, Frigon N, Hong J (1999) Purification and cloning of amyloid precursor protein β-secretase from human brain. Nature 402(6761):537–540
Tetko IV, Tanchuk VY (2002) Application of associative neural networks for prediction of lipophilicity in ALOGPS 2.1 program. J Chem Inf Comput Sci 42:1136–1145
Tetko IV, Tanchuk VY, Villa AE (2001) Prediction of n-octanol/water partition coefficients from PHYSPROP database using artificial neural networks and E-state indices. J Chem Inf Comput Sci 41:1407–1421
Van Der Spoel D, Lindahl E, Hess B, Groenhof G, Mark AE, Berendsen HJC (2005) GROMACS: fast, flexible, and free. J Comput Chem 26:1701–1718
Vassar R (2002) β-Secretase (BACE) as a drug target for Alzheimer’s disease. Adv Drug Deliv Rev 54(12):1589–1602
Verdon CM, Fossati P, Verny M, Dieudonne B, Teillet L, Nadel J (2007) Social cognition: an early impairment in dementia of the Alzheimer type. Alzheimer Dis Assoc Disord 21(1):25–30
Wallace AC, Laskowski RA, Thornton JM (1995) Ligplot-a program to generate schematic diagrams of protein ligand interactions. Protein Eng 8:127–134
Acknowledgments
The authors wish to thank the Vice-Provost for Research of the Shiraz University of Medical Sciences for the financial support to this project (Grant Number: 93-01-12-8102).
Author information
Authors and Affiliations
Corresponding author
Electronic supplementary material
Below is the link to the electronic supplementary material.
Rights and permissions
About this article
Cite this article
Razzaghi-Asl, N., Aggarwal, N., Srivastava, S. et al. Inhibition of Alzheimer’s BACE-1 by 2,6-dialkyl-4-chromon-3-yl-1,4-dihydropyridine-3,5-dicarboxylates. Med Chem Res 24, 3230–3241 (2015). https://doi.org/10.1007/s00044-015-1367-z
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00044-015-1367-z